{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T22:38:54Z","timestamp":1758148734718,"version":"3.44.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":201,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.rmcr.2025.102264","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T06:43:03Z","timestamp":1753339383000},"page":"102264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in two siblings with homozygous I1234V mutation cystic fibrosis: A prospective case series"],"prefix":"10.1016","volume":"57","author":[{"given":"Mohammed","family":"Alzaid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turki","family":"Alshahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raed","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gawahir","family":"Mukhtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alanood","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hammad","family":"Alsadoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safa","family":"Eltahir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Aldraihem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wadha","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10059","key":"10.1016\/j.rmcr.2025.102264_bib1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet Lond. Engl."},{"issue":"9678","key":"10.1016\/j.rmcr.2025.102264_bib2","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet Lond. Engl."},{"issue":"12","key":"10.1016\/j.rmcr.2025.102264_bib3","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1002\/ppul.26445","article-title":"Disparities and therapeutic advances in cystic fibrosis","volume":"59","author":"Palla","year":"2024","journal-title":"Pediatr. Pulmonol."},{"issue":"10212","key":"10.1016\/j.rmcr.2025.102264_bib4","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet Lond. Engl."},{"issue":"17","key":"10.1016\/j.rmcr.2025.102264_bib5","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmcr.2025.102264_bib7","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1569-1993(11)60014-3","article-title":"Recommendations for the classification of diseases as CFTR-related disorders","volume":"10","author":"Bombieri","year":"2011","journal-title":"J. Cyst. Fibros Off. J. Eur. Cyst. Fibros Soc."},{"issue":"4","key":"10.1016\/j.rmcr.2025.102264_bib8","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1183\/09031936.00228013","article-title":"CFTR: cystic fibrosis and beyond","volume":"44","author":"Mall","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmcr.2025.102264_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijpam.2019.12.002","article-title":"Geographic distribution of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Saudi Arabia","volume":"8","author":"Banjar","year":"2021","journal-title":"Int. J. Pediatr. Adolesc. Med."},{"issue":"3","key":"10.1016\/j.rmcr.2025.102264_bib10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jcf.2020.07.003","article-title":"CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation","volume":"20","author":"Phuan","year":"2021","journal-title":"J. Cyst. Fibros Off. J. Eur. Cyst. Fibros Soc."},{"issue":"4","key":"10.1016\/j.rmcr.2025.102264_bib11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jcf.2024.02.008","article-title":"Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation","volume":"23","author":"Aluma","year":"2024","journal-title":"J. Cyst. Fibros Off. J. Eur. Cyst. Fibros Soc."},{"issue":"8","key":"10.1016\/j.rmcr.2025.102264_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/gim.2014.4","article-title":"Genetic, cell biological, and clinical interrogation of the CFTR mutation c.3700 A>G (p.Ile1234Val) informs strategies for future medical intervention","volume":"16","author":"Molinski","year":"2014","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.rmcr.2025.102264_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/resp.13437","article-title":"Spectrum of mutations of cystic fibrosis in the 22 Arab countries: a systematic review","volume":"24","author":"Al-Sadeq","year":"2019","journal-title":"Respirol. Carlton Vic."},{"key":"10.1016\/j.rmcr.2025.102264_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106027","article-title":"Phenotypic and molecular characteristics of CF patients carrying the I1234V mutation","volume":"170","author":"El Bar Aluma","year":"2020","journal-title":"Respir. Med."},{"issue":"2","key":"10.1016\/j.rmcr.2025.102264_bib15","first-page":"135","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on Pseudomonas aeruginosa acquisition and chronic infection at a single pediatric cystic fibrosis care center","volume":"29","author":"Duehlmeyer","year":"2024","journal-title":"J. Pediatr. Pharmacol. Ther. JPPT"},{"key":"10.1016\/j.rmcr.2025.102264_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1245885","article-title":"Qualitative and quantitative evaluation of computed tomography changes in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: a retrospective observational study","volume":"14","author":"Dettmer","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.rmcr.2025.102264_bib17","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/ppul.26486","article-title":"Radiological and long-term clinical response to elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with advanced lung disease","volume":"58","author":"Aalbers","year":"2023","journal-title":"Pediatr. Pulmonol."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007125001005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007125001005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:45:56Z","timestamp":1758127556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007125001005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":16,"alternative-id":["S2213007125001005"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2025.102264","relation":{},"ISSN":["2213-0071"],"issn-type":[{"type":"print","value":"2213-0071"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in two siblings with homozygous I1234V mutation cystic fibrosis: A prospective case series","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2025.102264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102264"}}